Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

BACKGROUND: Due to economic constraints, cancer therapies are under close scrutiny by clinicians, pharmacists and payers alike. There is no published pharmacoeconomic evidence guiding the choice of first-line therapy for advanced renal cell carcinoma (RCC) in the Spanish setting. We aimed to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Villa, Guillermo, Hernández-Pastor, Luis-Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856525/
https://www.ncbi.nlm.nih.gov/pubmed/24004638
http://dx.doi.org/10.1186/1471-2407-13-399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856525/
https://www.ncbi.nlm.nih.gov/pubmed/24004638
http://dx.doi.org/10.1186/1471-2407-13-399

Ejemplares similares